These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34806308)

  • 1. Broadly neutralizing monoclonal antibodies for HIV prevention.
    Miner MD; Corey L; Montefiori D
    J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25829. PubMed ID: 34806308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants.
    Huang Y; Zhang L; Eaton A; Mkhize NN; Carpp LN; Rudnicki E; DeCamp A; Juraska M; Randhawa A; McDermott A; Ledgerwood J; Andrew P; Karuna S; Edupuganti S; Mgodi N; Cohen M; Corey L; Mascola J; Gilbert PB; Morris L; Montefiori DC
    Hum Vaccin Immunother; 2022 Dec; 18(1):1908030. PubMed ID: 34213402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
    LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
    PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadly Neutralizing Antibodies for HIV-1 Prevention.
    Walsh SR; Seaman MS
    Front Immunol; 2021; 12():712122. PubMed ID: 34354713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
    Mkhize NN; Yssel AEJ; Kaldine H; van Dorsten RT; Woodward Davis AS; Beaume N; Matten D; Lambson B; Modise T; Kgagudi P; York T; Westfall DH; Giorgi EE; Korber B; Anthony C; Mapengo RE; Bekker V; Domin E; Eaton A; Deng W; DeCamp A; Huang Y; Gilbert PB; Gwashu-Nyangiwe A; Thebus R; Ndabambi N; Mielke D; Mgodi N; Karuna S; Edupuganti S; Seaman MS; Corey L; Cohen MS; Hural J; McElrath MJ; Mullins JI; Montefiori D; Moore PL; Williamson C; Morris L
    PLoS Pathog; 2023 Jun; 19(6):e1011469. PubMed ID: 37384759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features.
    Juraska M; Bai H; deCamp AC; Magaret CA; Li L; Gillespie K; Carpp LN; Giorgi EE; Ludwig J; Molitor C; Hudson A; Williamson BD; Espy N; Simpkins B; Rudnicki E; Shao D; Rossenkhan R; Edlefsen PT; Westfall DH; Deng W; Chen L; Zhao H; Bhattacharya T; Pankow A; Murrell B; Yssel A; Matten D; York T; Beaume N; Gwashu-Nyangiwe A; Ndabambi N; Thebus R; Karuna ST; Morris L; Montefiori DC; Hural JA; Cohen MS; Corey L; Rolland M; Gilbert PB; Williamson C; Mullins JI
    Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2308942121. PubMed ID: 38241441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
    Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
    Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D;
    Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.
    Chen X; Zhou T; Schmidt SD; Duan H; Cheng C; Chuang GY; Gu Y; Louder MK; Lin BC; Shen CH; Sheng Z; Zheng MX; Doria-Rose NA; Joyce MG; Shapiro L; Tian M; Alt FW; Kwong PD; Mascola JR
    Immunity; 2021 Feb; 54(2):324-339.e8. PubMed ID: 33453152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
    Corey L; Gilbert PB; Juraska M; Montefiori DC; Morris L; Karuna ST; Edupuganti S; Mgodi NM; deCamp AC; Rudnicki E; Huang Y; Gonzales P; Cabello R; Orrell C; Lama JR; Laher F; Lazarus EM; Sanchez J; Frank I; Hinojosa J; Sobieszczyk ME; Marshall KE; Mukwekwerere PG; Makhema J; Baden LR; Mullins JI; Williamson C; Hural J; McElrath MJ; Bentley C; Takuva S; Gomez Lorenzo MM; Burns DN; Espy N; Randhawa AK; Kochar N; Piwowar-Manning E; Donnell DJ; Sista N; Andrew P; Kublin JG; Gray G; Ledgerwood JE; Mascola JR; Cohen MS;
    N Engl J Med; 2021 Mar; 384(11):1003-1014. PubMed ID: 33730454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition.
    Seaton KE; Huang Y; Karuna S; Heptinstall JR; Brackett C; Chiong K; Zhang L; Yates NL; Sampson M; Rudnicki E; Juraska M; deCamp AC; Edlefsen PT; Mullins JI; Williamson C; Rossenkhan R; Giorgi EE; Kenny A; Angier H; Randhawa A; Weiner JA; Rojas M; Sarzotti-Kelsoe M; Zhang L; Sawant S; Ackerman ME; McDermott AB; Mascola JR; Hural J; McElrath MJ; Andrew P; Hidalgo JA; Clark J; Laher F; Orrell C; Frank I; Gonzales P; Edupuganti S; Mgodi N; Corey L; Morris L; Montefiori D; Cohen MS; Gilbert PB; Tomaras GD
    EBioMedicine; 2023 Jul; 93():104590. PubMed ID: 37300931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial.
    Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C; Pantaleo G; Andrew P; Karg C; He Z; Lu H; Paez CA; Baumblatt JAG; Polakowski LL; Chege W; Anderson MA; Janto S; Han X; Huang Y; Dumond J; Ackerman ME; McDermott AB; Flach B; Piwowar-Manning E; Seaton K; Tomaras GD; Montefiori DC; Gama L; Mascola JR;
    PLoS Med; 2024 Jun; 21(6):e1004329. PubMed ID: 38913710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.
    Awan SF; Happe M; Hofstetter AR; Gama L
    Curr Opin HIV AIDS; 2022 Jul; 17(4):247-257. PubMed ID: 35762380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.
    Gilbert PB; Juraska M; deCamp AC; Karuna S; Edupuganti S; Mgodi N; Donnell DJ; Bentley C; Sista N; Andrew P; Isaacs A; Huang Y; Zhang L; Capparelli E; Kochar N; Wang J; Eshleman SH; Mayer KH; Magaret CA; Hural J; Kublin JG; Gray G; Montefiori DC; Gomez MM; Burns DN; McElrath J; Ledgerwood J; Graham BS; Mascola JR; Cohen M; Corey L
    Stat Commun Infect Dis; 2017 Jan; 9(1):. PubMed ID: 29218117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadly Neutralizing Antibodies for HIV Prevention.
    Karuna ST; Corey L
    Annu Rev Med; 2020 Jan; 71():329-346. PubMed ID: 31986089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review.
    Mahomed S; Garrett N; Baxter C; Abdool Karim Q; Abdool Karim SS
    J Infect Dis; 2021 Feb; 223(3):370-380. PubMed ID: 32604408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
    van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
    J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS.
    Wesley MS; Chiong KT; Seaton KE; Arocena CA; Sawant S; Hare J; Hernandez K; Rojas M; Heptinstall J; Beaumont D; Crisafi K; Nkolola J; Barouch DH; Sarzotti-Kelsoe M; Tomaras GD; Yates NL
    Front Immunol; 2021; 12():709994. PubMed ID: 34504492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry.
    Khan SN; Sok D; Tran K; Movsesyan A; Dubrovskaya V; Burton DR; Wyatt RT
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.